Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Trial shows promise for facial tumour cure
Lead author Dr Cesar Tovar said the findings confirm it is possible to trigger the devil’s immune system to recognise and destroy DFTD tumours.
Immunotherapy shrank tumours in Tasmanian devils

Scientists say they have had a ‘eureka’ moment in using immunotherapy to cure Tasmanian devils of the deadly devil facial tumour disease (DFTD).

Led by the University of Tasmania, an international research team used immunotherapy on devils with golf-ball-sized tumours and observed the tumours shrinking and disappearing over a period of three months.

“This is almost a eureka moment for us because it’s the first time we can say for sure that it was the immunotherapy that was making the tumour shrink,” said Professor Greg Woods, who led the team at the university’s Menzies Institute for Medical Research.

Lead author Dr Cesar Tovar added that the findings confirm it is possible to trigger the devil’s immune system to recognise and destroy DFTD tumours.

“Our research shows that a DFTD vaccine is feasible. We are focusing our efforts on developing strategies to improve the devils’ response to immunisation.”

The breakthrough is the next step on from research published in 2015, which revealed the devil’s immune system was capable of mounting an immune response to DFTD.

“This is an important step along the way to developing a vaccine to protect against DFTD and potentially to cure devils of established DFTD,” Prof Woods added.

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.